113173
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
免疫检查点相关基因多态性以及高血清浓度的 PD-L1 和 CTLA4 会导致宫颈癌对铂类化疗耐药
Authors Yuan H, Wang X, Liu K, Zhang J, Wang P
Received 9 October 2025
Accepted for publication 18 December 2025
Published 30 December 2025 Volume 2025:17 Pages 5719—5731
DOI https://doi.org/10.2147/IJWH.S569408
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Vinay Kumar
Hongqin Yuan,* Xinfeng Wang,* Kaidong Liu, Jia Zhang, Pei Wang
Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Pei Wang, Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, # 3, Zhigong New Street, Xinghualing District, Taiyuan, Shanxi, 030013, People’s Republic of China, Email wangpei674325@163.com
Purpose: This study aims to evaluate the feasibility of using immune checkpoint-related gene polymorphisms and serum levels of PD-1, PD-L1 and CTLA4 in predicting chemotherapy resistance in patients with cervical cancer.
Methods: Seven candidate SNPs in PDCD1, CD274 and CTLA4 were genotyped in 1032 cervical cancer patients (537 non-responders and 495 responders based on their responses to chemotherapy), and the serum level of PD-1, PD-L1 and CTLA4 was detected by ELISA.
Results: The frequencies of minor allele A of PDCD1- rs2227982, CD274-rs2890658 and CTLA4-rs3087243 were significantly higher in non-responders than that in responders (p ≤ 0.0001). Moreover, the genotype AA of the three SNPs was associated with a 2.24, 3.78 and 2.71-fold increase in susceptibility to platinum resistance, respectively (p ≤ 0.0001). In addition, all of the three SNPs were associated with the risk of cisplatin resistance in both patients with squamous cell carcinoma and adenocarcinoma under different genetic models (p < 0.05). The serum concentrations of PD-L1 and CTLA4 in the non-responder group were significantly higher than those in the responder group (p < 0.0001). Moreover, the PD-L1 and CTLA4 levels of carriers with mutant genotypes of CD274-rs2890658 and CTLA4-rs3087243 were significantly higher than those of with wild-type, and the serum levels of homozygous mutant carriers were even higher (p < 0.0001).
Conclusion: The PDCD1- rs2227982, CD274-rs2890658 and CTLA4- rs3087243 polymorphisms and high serum levels of PD-L1 and CTLA4 may predict chemotherapy resistance in cervical cancer patients.
Keywords: platinum-based chemotherapy, chemotherapy resistance, cervical cancer, PD-L1, CTLA4
Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, 030013, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Pei Wang, Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, # 3, Zhigong New Street, Xinghualing District, Taiyuan, Shanxi, 030013, People’s Republic of China, Email wangpei674325@163.com
Purpose: This study aims to evaluate the feasibility of using immune checkpoint-related gene polymorphisms and serum levels of PD-1, PD-L1 and CTLA4 in predicting chemotherapy resistance in patients with cervical cancer.
Methods: Seven candidate SNPs in PDCD1, CD274 and CTLA4 were genotyped in 1032 cervical cancer patients (537 non-responders and 495 responders based on their responses to chemotherapy), and the serum level of PD-1, PD-L1 and CTLA4 was detected by ELISA.
Results: The frequencies of minor allele A of PDCD1- rs2227982, CD274-rs2890658 and CTLA4-rs3087243 were significantly higher in non-responders than that in responders (p ≤ 0.0001). Moreover, the genotype AA of the three SNPs was associated with a 2.24, 3.78 and 2.71-fold increase in susceptibility to platinum resistance, respectively (p ≤ 0.0001). In addition, all of the three SNPs were associated with the risk of cisplatin resistance in both patients with squamous cell carcinoma and adenocarcinoma under different genetic models (p < 0.05). The serum concentrations of PD-L1 and CTLA4 in the non-responder group were significantly higher than those in the responder group (p < 0.0001). Moreover, the PD-L1 and CTLA4 levels of carriers with mutant genotypes of CD274-rs2890658 and CTLA4-rs3087243 were significantly higher than those of with wild-type, and the serum levels of homozygous mutant carriers were even higher (p < 0.0001).
Conclusion: The PDCD1- rs2227982, CD274-rs2890658 and CTLA4- rs3087243 polymorphisms and high serum levels of PD-L1 and CTLA4 may predict chemotherapy resistance in cervical cancer patients.
Keywords: platinum-based chemotherapy, chemotherapy resistance, cervical cancer, PD-L1, CTLA4